BCL2 and Miyoshi myopathy: Moreover, due to the substantial response rates of venetoclax in patients with relapsed/refractory myeloma (RRMM) with t(11;14), the BCL2 dependency seems to be a major driver for the progression of the MM disease, also within the clonal evolution.